CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
1.775
0.00 (0.00%)
Aug 14, 2025, 11:33 AM - Market open

CytomX Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
47.9831.87-0.57-99.32-115.87-64.82
Upgrade
Depreciation & Amortization
1.571.772.182.442.712.57
Upgrade
Asset Writedown & Restructuring Costs
0.110.11-0.25--
Upgrade
Loss (Gain) From Sale of Investments
-2.86-5.31-7.42-0.050.27-0.24
Upgrade
Stock-Based Compensation
7.327.678.5613.1313.1714.79
Upgrade
Other Operating Activities
4.284.083.733.413.132.89
Upgrade
Change in Accounts Receivable
0.910.3332.55-35.20.01-0.79
Upgrade
Change in Accounts Payable
-0.3-0.3-1.430.07-0.14-0.86
Upgrade
Change in Unearned Revenue
-128.19-118.25-89.0116.57-33.9562.83
Upgrade
Change in Other Net Operating Assets
-8.25-8.2-4.63-12.0911.64-11.12
Upgrade
Operating Cash Flow
-77.43-86.23-56.04-110.79-119.035.26
Upgrade
Capital Expenditures
-0.25-0.31-0.84-1.74-1.61-2.31
Upgrade
Investment in Securities
-12.22100.01-149.8310024.1-16.41
Upgrade
Investing Cash Flow
-12.4699.7-150.6798.2622.49-18.72
Upgrade
Issuance of Common Stock
95.87.520.560.65110.2116.89
Upgrade
Other Financing Activities
--29.67---
Upgrade
Financing Cash Flow
95.87.5230.230.65110.2116.89
Upgrade
Net Cash Flow
5.9120.99-176.48-11.8813.673.43
Upgrade
Free Cash Flow
-77.68-86.54-56.88-112.53-120.642.95
Upgrade
Free Cash Flow Margin
-55.05%-62.66%-56.19%-211.67%-323.33%4.31%
Upgrade
Free Cash Flow Per Share
-0.80-1.02-0.77-1.71-1.880.06
Upgrade
Levered Free Cash Flow
-69.25-44.243.66-8.92-46.11-53.86
Upgrade
Unlevered Free Cash Flow
-69.25-44.243.66-8.92-46.11-53.86
Upgrade
Change in Working Capital
-135.83-126.42-62.51-30.65-22.4450.07
Upgrade
Updated May 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q